Search

Your search keyword '"Wang, Eunice S."' showing total 71 results

Search Constraints

Start Over You searched for: Author "Wang, Eunice S." Remove constraint Author: "Wang, Eunice S." Database Complementary Index Remove constraint Database: Complementary Index
71 results on '"Wang, Eunice S."'

Search Results

1. Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.

2. Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.

3. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

4. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.

5. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.

6. Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia.

7. Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status.

8. A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.

9. Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches.

10. Mutant PPM1D - and TP53 -Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy.

13. Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States.

14. A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia.

17. Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy.

18. A precision medicine classification for treatment of acute myeloid leukemia in older patients.

19. A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia.

20. Novel therapies for AML: a round-up for clinicians.

22. Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study.

23. Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia.

24. Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors.

26. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.

27. Advances in immunotherapy for acute myeloid leukemia.

28. Advances in immunotherapy for acute myeloid leukemia.

29. Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML.

31. Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib.

37. Acceptability, Feasibility, and Efficacy of a Supportive Group Intervention for Caregivers of Newly Diagnosed Leukemia Patients.

40. Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia.

41. Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia.

44. CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations.

45. Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia.

46. Image cytometry-based detection of aneuploidy by fluorescence in situ hybridization in suspension.

47. Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia.

49. Smoking adversely affects survival in acute myeloid leukemia patients.

50. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population.

Catalog

Books, media, physical & digital resources